Company: LIMN
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001104659-25-010605
Chunk: 516

Company: Liminatus Pharma, Inc.
Filing Date: 2025-02-07
Form: 424B3
Chunk 516
---
, to ensure that these unaudited condensed financial statements include appropriate disclosure of events both recognized in the unaudited condensed financial statements and events which occurred but were not recognized in the unaudited condensed financial statements.

On October 23, 2024, the Company entered into a sixth amendment to the Business Combination Agreement to, among other things, reduce the enterprise value associated with the Company to $175 million.

On November 1, 2024, the Company borrowed $0.4 million from Amantes LLC (“Amantes”), a related party of the Company due to having common executives, pursuant to a Loan Agreement between the Company and Amantes (the “Amantes Loan”). The Amantes Loan bears interest at 6% per annum and is due on January 1, 2025. The Company and Amantes have mutually agreed to defer repayment of this loan until the completion of the Company’s business combination with Iris.

On November 27, 2024, the Amended Note was further amended to increase the aggregate principal amount up to $5.0 million.

On November 27, 2024, the Company borrowed an additional $0.3 million from Amantes (the “Additional Amantes Loan”). The Additional Amantes Loan bears interest at 6% per annum and is due on January 1, 2025, which may be extended upon mutual agreement of the parties. The Company and Amantes have mutually agreed to defer repayment of this loan until the completion of the Company’s business combination with Iris.

On November 1, 2024, December 2, 2024, and January 7, 2025, the Company funded additional advances under the Amended Note, as discussed in Note 7 to these unaudited condensed financial statements, of $0.8 million.

<div align='center'>F-68</div>

TABLE OF CONTENTS

#### LIMINATUS PHARMA, LLC

### NOTES TO CONDENSED FINANCIAL STATEMENTS

#### SEPTEMBER 30, 2024
<div align='center'>**(Unaudited)**</div>

On December 26, 2024, the Company entered into a seventh amendment to the Business Combination Agreement extending the outside date to June 30, 2025.

On December 26, 2024, Iris, Iris Parent Holding Corp. and the Company entered into a sixth amendment to the equity subscription agreement with Ewon extending the deadline for which the subscriber can terminate the agreement to June